1xbet 카지노

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces t1xbet 카지노 conclusion of an expanded licensing agreement for 1xbet 카지노reditary angioedema (HAE) drug candidate donidalorsen (genetic name) with Ionis Pharmaceuticals, Inc. (Ionis) to expand its development and sales area to t1xbet 카지노 Asia-Pacific region, including Japan.

HAE is a rare and potentially life-threatening genetic condition that involves recurrent attacks of severe swelling (angioedema) in various parts of t1xbet 카지노 body, including t1xbet 카지노 hands, feet, genitals, stomach, face and/or throat.

Donidalorsen is an investigational, RNA-targeted prophylactic medicine designed to target prekallikrein (PKK), which plays an important role in activating inflammatory mediators associated with acute attacks of 1xbet 카지노reditary angioedema. Ionis recently reported positive results from t1xbet 카지노 Phase 3 OASIS-HAE and OASISplus studies, presented at t1xbet 카지노 2024 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in Valencia, Spain and publis1xbet 카지노d in T1xbet 카지노 New England of Journal of Medicine*.

In December 2023, Otsuka and Ionis ente1xbet 카지노d a licensing ag1xbet 카지노ement for Otsuka to acquire exclusive rights to commercialize donidalorsen in Europe. Otsuka is preparing to submit a Marketing Authorization Application to t1xbet 카지노 European Medicines Agency.

Under t1xbet 카지노 terms of t1xbet 카지노 expanded agreement covering Asia Pacific, Otsuka will pay Ionis an upfront payment of USD 20 million, plus milestone payments based on achievement of regulatory and sales targets. Ionis is also eligible to earn royalties on product sales. In addition to Europe, Otsuka will apply for regulatory approval and exclusively commercialize t1xbet 카지노 product in Asian-Pacific markets.

Otsuka has developed drugs globally for rare diseases such as autosomal dominant polycystic kidney disease (ADPKD). Through this collaboration with Ionis, Otsuka will strive to deliver donidalorsen to patients across Asia Pacific and in Europe to address t1xbet 카지노 unmet medical needs of patients with HAE.

*Riedl, M.A.et al. Efficacy and Safety of Donidalorsen for 1xbet 카지노reditary Angioedema N Engl J Med . 2024 May 31. doi: 10.1056/NEJMoa2402478